Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, Canada.
Addiction. 2017 Sep;112(9):1669-1679. doi: 10.1111/add.13851. Epub 2017 Jun 6.
Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use.
A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires.
Data were collected across 17 hospitals in France.
All HIV-HCV co-infected patients who initiated HCV treatment during follow-up and answered items regarding substance use in at least one yearly questionnaire (258 patients, 671 visits).
HCV treatment consisted of Peg-IFN-based regimens.
Four time-varying outcomes: hazardous alcohol use (Alcohol Use Disorders Identification Test-C > 3/4 for women/men), number of alcohol units/month, binge drinking, cannabis and tobacco use. Mixed models assessed the effect of HCV treatment status (not yet treated, treated and HCV-cleared, treated and HCV-chronic) on each outcome.
A significant decrease (more than 60% reduction) in both hazardous alcohol use and binge drinking and a reduction of 10 alcohol units/month was observed after HCV treatment (irrespective of HCV clearance). No significant effect of HCV treatment status was found on tobacco use and regular cannabis use, but HCV 'clearers' reported less non-regular use of cannabis.
Hepatitis C virus (HCV) treatment appears to help HIV-HCV co-infected patients reduce alcohol use.
关于丙型肝炎病毒（HCV）治疗前后物质使用模式变化的数据很少。我们使用 HIV-HCV 合并感染个体的纵向数据，研究接受聚乙二醇干扰素（Peg-IFN）治疗是否会改变烟草、大麻和酒精的使用情况，无论 HCV 是否清除。
从 2006 年开始，我们招募了 HIV-HCV 合并感染的前瞻性队列研究。从病历中获取参与者的临床数据，并通过每年的自我管理问卷收集社会人口统计学和行为特征。
数据收集在法国的 17 家医院进行。
所有在随访期间开始 HCV 治疗并在至少一份年度问卷中回答了关于物质使用问题的 HIV-HCV 合并感染患者（258 名患者，671 次就诊）。
HCV 治疗包括 Peg-IFN 为基础的方案。
四个时间变化的结果：危险饮酒（女性/男性的酒精使用障碍识别测试-C > 3/4）、每月饮酒量、狂饮、大麻和烟草使用。混合模型评估 HCV 治疗状态（尚未治疗、已治疗且 HCV 清除、已治疗且 HCV 慢性）对每个结果的影响。
在 HCV 治疗后（无论 HCV 是否清除），危险饮酒和狂饮显著减少（减少 60%以上），每月饮酒量减少 10 个单位。HCV 治疗状态对烟草使用和定期使用大麻没有显著影响，但 HCV“清除者”报告的非定期使用大麻减少。
丙型肝炎病毒（HCV）治疗似乎有助于 HIV-HCV 合并感染患者减少酒精使用。
